MA39054A1 - Bicyclic pyridyl derivatives with fused rings used as fgfr4 inhibitors - Google Patents

Bicyclic pyridyl derivatives with fused rings used as fgfr4 inhibitors

Info

Publication number
MA39054A1
MA39054A1 MA39054A MA39054A MA39054A1 MA 39054 A1 MA39054 A1 MA 39054A1 MA 39054 A MA39054 A MA 39054A MA 39054 A MA39054 A MA 39054A MA 39054 A1 MA39054 A1 MA 39054A1
Authority
MA
Morocco
Prior art keywords
fused rings
rings used
pyridyl derivatives
fgfr4 inhibitors
bicyclic
Prior art date
Application number
MA39054A
Other languages
French (fr)
Other versions
MA39054B1 (en
Inventor
Pascal Furet
Lv Liao
Robin Alec Fairhurst
Nicole Buschmann
Thomas Knöpfel
Catherine Leblanc
Robert Mah
Pierre Nimsgern
Sebastien Ripoche
Jing Xiong
Xianglin Zhao
Bo Han
Can Wang
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Priority claimed from PCT/IB2014/065585 external-priority patent/WO2015059668A1/en
Publication of MA39054A1 publication Critical patent/MA39054A1/en
Publication of MA39054B1 publication Critical patent/MA39054B1/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La présente invention porte sur un composé de formule (i) ou un sel pharmaceutiquement acceptable de ce dernier; sur un procédé de préparation des composés de l'invention et sur leurs utilisations thérapeutiques. L'invention concerne également une combinaison d'agents actifs du point de vue pharmacologique et une composition pharmaceutique comprenant ledit composé.The present invention relates to a compound of formula (i) or a pharmaceutically acceptable salt thereof; on a process for preparing the compounds of the invention and on their therapeutic uses. The invention also relates to a combination of pharmacologically active agents and a pharmaceutical composition comprising said compound.

MA39054A 2013-10-25 2014-10-24 Bicyclic pyridyl derivatives with fused rings used as fgfr4 inhibitors MA39054B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2013086003 2013-10-25
PCT/IB2014/065585 WO2015059668A1 (en) 2013-10-25 2014-10-24 Ring-fused bicyclic pyridyl derivatives as fgfr4 inhibitors

Publications (2)

Publication Number Publication Date
MA39054A1 true MA39054A1 (en) 2018-02-28
MA39054B1 MA39054B1 (en) 2018-09-28

Family

ID=53491699

Family Applications (1)

Application Number Title Priority Date Filing Date
MA39054A MA39054B1 (en) 2013-10-25 2014-10-24 Bicyclic pyridyl derivatives with fused rings used as fgfr4 inhibitors

Country Status (4)

Country Link
AR (1) AR098145A1 (en)
MA (1) MA39054B1 (en)
TW (2) TWI673268B (en)
UY (1) UY35792A (en)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0906472D0 (en) * 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
GB201118656D0 (en) * 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds

Also Published As

Publication number Publication date
UY35792A (en) 2015-05-29
AR098145A1 (en) 2016-05-04
TW201605853A (en) 2016-02-16
TWI690528B (en) 2020-04-11
TW201938560A (en) 2019-10-01
TWI673268B (en) 2019-10-01
MA39054B1 (en) 2018-09-28

Similar Documents

Publication Publication Date Title
MA42678B1 (en) NEW SUBSTITUTED NUCLEOSIDE ANALOGS WITH BICYCLIC AROMATIC CYCLE 6-6 FOR USE AS PRMT5 INHIBITORS
MA37834A1 (en) 1,4-Disubstituted pyridazine analogs and methods of treating disorders related to Mn deficiency
MA42230B1 (en) Bicyclic derivatives, process for their preparation, and pharmaceutical compositions containing them
EA201690848A1 (en) Derivatives of Bicyclic Pyridyl with Condensed Rings as FGFR4 Inhibitors
MA34837B1 (en) INDOLIC COMPOUNDS OR ANALOGS THEREFOR USEFUL IN THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD)
MA38325A2 (en) Benzothiophene derivatives and compositions thereof as selective estrogen receptor degradation agents
MA37866B1 (en) Aza-indazole or diaza-indazole derivatives for the treatment of pain
MA37477A1 (en) Modulators of complement pathways and their uses
MA46101B1 (en) Positive allosteric modulators of the m1 muscarinic receptor
MA39983B1 (en) Carboxamide derivatives
MA37405A1 (en) Heterocyclyl compounds
MA42341B2 (en) Protein kinase inhibitor, method of preparation and medical use
MA38330B1 (en) Butanoic phosphonic acid derivatives of bisphenol substituted as nep inhibitors (neutral endopeptidase)
MA38865A1 (en) Formulation comprising a lipid-lowering agent
EA201692542A1 (en) INDANEOUS AND INDOLINE DERIVATIVES AND THEIR APPLICATION AS ACTIVATORS OF SOLUBLE GUANYLATSYCLASES
MA35032B1 (en) GLYCOSIDE DERIVATIVES AND THEIR USES IN THE TREATMENT OF DIABETES
PE20240930A1 (en) BENZOAZEPINE ANALOGS AS INHIBITING AGENTS OF BRUTON'S TYROSINE KINASE
MA49127B1 (en) N-substituted indole derivatives
MA40875A (en) 2,4-DIAMINO-QUINOLEIN SUBSTITUTED AS NEW ANTI-CANCER AGENTS
MA38679A1 (en) Cxcr7 receiver modulators
MA45782B1 (en) Modulators of the cxcr7 piperidine receptor
MA39165A1 (en) Benzimidazole-proline derivatives for their use in the treatment of crepuscular state syndrome
MA43913A (en) POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC M1 RECEPTOR
MA38854B1 (en) Amide derivatives used as lysophosphatidic acid receptor antagonists
MA42769B1 (en) Fluoroindole derivatives as positive allosteric modulators of the m1 muscarinic receptor